المؤلفون: D. Andreev A., A. Zavyalov A., Д. Андреев А., А. Завьялов А.

المصدر: Malignant tumours; Том 12, № 1 (2022); 5-12 ; Злокачественные опухоли; Том 12, № 1 (2022); 5-12 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: auditing, lung cancer, quality assurance, patient‑ oriented approaches, health information technologies, review, обзор, рак легкого, контроль качества, аудит, автоматизация, онкоинформатика, обратная связь

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/923/666; Zhang Y., Ren J.‑S., Huang H.‑Y., Shi J.‑F., Li N., Zhang Y., et al. International trends in lung cancer incidence from 1973 to 2007. // Cancer Med. 2018. Vol. 7, № 4. P. 1479–1489.; Слугин Е. Н., Левченко Е. В., Имянитов Е. Н., Лопушанская О. О. Оценка роли мутации EGFR при определении тактики хирургического лечения немелкоклеточного рака легкого. // Вопросы онкологии. 2021. Vol. 67, № 3. P. 315–322.; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). / ed. Каприн А. Д., Старинский В. В., Шахзадова А. О. Москва: МНИОИ им. П. А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 p.; Андреев Д. А., Завьялов А. А., Полякова К. И., Давыдовская М. В. Ингибиторы тирозинкиназ в лечении распространенного рака легкого на примере системы льготного лекарственного обеспечения города Москвы. // Пульмонология. 2020. Vol. 30, № 4. P. 463–472.; Longkanker Nederland. IKNL. Cijfers over longkanker. [Electronic resource]. 2021. URL: https://www.longkankernederland.nl/longkanker/statistieken (accessed: 20.08.2021).; Андреев Д. А., Завьялов А. А., Кашурников А. Ю. Организация контроля качества и безопасности медицинской деятельности по профилю “онкология” на примере стран Западной Европы. // Здравоохранение Российской Федерации. 2020. Vol. 64, № 6. P. 311–317.; Завьялов А. А., Андреев Д. А. Организация контроля качества радиотерапии путем автоматизации процессинга больших массивов данных. // Здравоохранение Российской Федерации. 2020. Vol. 64, № 6. P. 368–372.; Van Leersum N. J., Snijders H. S., Henneman D., Kolfschoten N. E., Gooiker G. A., ten Berge M. G., et al. The Dutch surgical colorectal audit. // Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. England, 2013. Vol. 39, № 10. P. 1063–1070.; Beck N., van Bommel A. C., Eddes E. H., van Leersum N. J., Tollenaar R. A., Wouters M. W. The Dutch Institute for Clinical Auditing: Achieving Codman’s Dream on a Nationwide Basis. // Ann Surg. United States, 2020. Vol. 271, № 4. P. 627–631.; Neuhauser D. Ernest Amory Codman MD. // Qual Saf Health Care. 2002. Vol. 11, № 1. P. 104–105.; Wouters M. W. J. M. Kwaliteitsregistraties volgens het principe van ‘clinical auditing’ // Tijdschr voor Urol. 2017. Vol. 7, № 2. P. 60–72.; DICA. Dutch Lung Cancer Audit. [Electronic resource]. 2021. URL: https://dica.nl/dlca/home (accessed: 24.06.2021).; Beck N., Hoeijmakers F., Wiegman E. M., Smit H. J. M., Schramel F. M., Steup W. H., et al. Lessons learned from the Dutch Institute for Clinical Auditing: the Dutch model for quality assurance in lung cancer treatment. // J Thorac Dis. 2018. Vol. 10, № Suppl 29. P. S3472–S3485.; DICA. Het Codman Dashboard. [Electronic resource]. 2021. URL: https://dica.nl/codmandashboard (accessed: 25.06.2021).; DICA. Basisitabel DLCA-L (2016‑2019). [Electronic resource]. URL: https://dica.nl/media/2377/BasistabelDLCA-L2019.jpg (accessed: 24.06.2021).; DICA. Basistabel DLCA-S (2015‑2019). [Electronic resource]. URL: https://dica.nl/media/2376/DLCA-Sbasistabel2019.jpg.; DICA. Basistabel DLCA-R (2015‑2019). [Electronic resource]. URL: https://dica.nl/media/2375/DLCA-Rbasistabel2019.jpg (accessed: 24.06.2021).; DICA. DLCA Indicatorenset verslagjaar 2019. [Electronic resource]. 2019. URL: https://dica.nl/dlca/documenten (accessed: 20.08.2021).; DICA. Handleiding DLCA-L. Dutch Lung Cancer Audit – Lung Oncology (versie 1.0). [Electronic resource]. 2020. URL: https://dica.nl/dlca/documenten (accessed: 24.06.2021).; Ismail R. K., Schramel F. M. N. H., van Dartel M., Hilarius D. L., de Boer A., Wouters M. W. J. M., et al. The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients. // Lung Cancer. Ireland, 2020. Vol. 149. P. 68–77.; MRDM. Handleiding Survey. [Electronic resource]. 2019. URL: https://dica.nl/dlca/documenten (accessed: 24.06.2021).; van Dorp M., Beck N., Steup W. H., Schreurs W. H. Surgical treatment of pulmonary metastases in the Netherlands: data from the Dutch Lung Cancer Audit for Surgery. // Eur J cardio‑thoracic Surg Off J Eur Assoc Cardio‑thoracic Surg. Germany, 2020. Vol. 58, № 4. P. 768–774.; Van Bockel L., Van Der Woude L., De Jaeger K., Coremans I., Damhuis R., Van Es C., et al. P21.03 Dutch Lung Cancer Audit‑Radiotherapy: Real‑World Data on Stage III Non‑Small Cell Lung Cancer Treated With Radiotherapy Only // J Thorac Oncol. Elsevier BV, 2021. Vol. 16, № 3. P. S364.; Walraven I., Damhuis R. A., Ten Berge M. G., Rosskamp M., van Eycken L., de Ruysscher D., et al. Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non‑Small Cell Lung Cancer Patients in the Netherlands and Belgium. // Clin Oncol (R Coll Radiol). England, 2017. Vol. 29, № 11. P. e177–e185.; DICA. DLCA. Veelgestelde vragen. [Electronic resource]. 2021. URL: https://dica.nl/dlca/veelgestelde-vragen (accessed: 20.08.2021).; https://www.malignanttumors.org/jour/article/view/923

الاتاحة: https://www.malignanttumors.org/jour/article/view/923
https://doi.org/10.18027/2224-5057-2022-12-1-5-12

المؤلفون: N. Novikova A., Z. Salpagarova K., M. Chashkina I., A. Bykova A., Z. Alimova A., А. Yadykina S., D. Mesitskaya F., N. Babakova A., D. Andreev A., Н. Новикова А., З. Салпагарова К., М. Чашкина И., А. Быкова А., З. Алимова А., А. Ядыкина С., Д. Меситская Ф., Н. Бабакова А., Д. Андреев А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 186-192 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 186-192 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: atrial fibrillation, chronic kidney disease, anticoagulants, warfarin, bleeding, фибрилляция предсердий, антикоагулянтная терапия, хроническая болезнь почек, кровотечения, скорость клубочковой фильтрации

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2426/2136; https://www.rpcardio.com/jour/article/view/2426/2167; Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.005119.; Якусевич В.В., Позднякова Е.М., Якусевич В.В., и др. Амбулаторный пациент с фибрилляцией предсердий: основные характеристики. Первые данные регистра РЕКВАЗА ФП-ЯРОСЛАВЛЬ. Рациональная Фармакотерапия в Кардиологии. 2015;11(2):149- 52. DOI:10.20996/1819-6446-2015-11-2-149-152.; Валиахметов М.Н., Гомова Т.А., Лукьянов М.М., и др. Больные с фибрилляцией предсердий в условиях многопрофильного стационара: структура госпитализации, сочетанные сердечно-сосудистые заболевания и медикаментозная терапия (данные регистра РЕКВАЗА ФП-ТУЛА). Рациональная Фармакотерапия в Кардиологии. 2017;13(4):495-505. DOI:10.20996/1819-6446-2017-13-4-495-505.; Тучков А.А., Гоголашвили Н.Г., Яскевич Р.А. Оценка динамики антитромботической терапии у пациентов с фибрилляцией предсердий в течение 2015-2017 гг. по данным регистра клиники Научно-исследовательского института медицинских проблем Севера г. Красноярска. Рациональная Фармакотерапия в Кардиологии 2019;15(1):43-8. DOI:10.20996/1819-6446-2019-15-1-43-48.; Чашкина М.И., Козловская Н.Л., Андреев Д.А., и др. Распространенность хронической болезни почек поздних стадий у пациентов с неклапанной фибрилляцией предсердий, госпитализированных в кардиологические отделения. Кардиология. 2020;60(2):41-6. DOI:10.18087/cardio.2020.2.n823.; Patino MI, Kraus P, Bishop MA. Implementation of patient education software in an anticoagulation clinic to decrease visit times for new patient appointments. Patient Educ Couns. 2019;102(5):961-7. DOI:10.1016/j.pec.2018.12.023.; Haut ER, Aboagye JK, Shaffer DL, et al. Effect of Real-time Patient-Centered Education Bundle on Administration of Venous Thromboembolism Prevention in Hospitalized Patients. JAMA Netw Open. 2018;1(7):e184741. DOI:10.1001/jamanetworkopen.2018.4741.; Reinecke H, nabauer M, Gerth A, et al. Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney International. 2015;87(1):200-9. DOI:10.1038/ki.2014.195.; Albrecht D, Turakhia M, Ries D, et al. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease. Thrombosis and Haemostasis. 2017;117(11):2026-33. DOI:10.1160/TH16-10-0815.; Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles. Clinical Journal of the American Society of Nephrology. 2018;13(7):1085-95. DOI:10.2215/CJN.00340118.; Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.; Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139-51. DOI:10.1056/NEJ- Moa0905561.; Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal. 2012;33(22):2821-30. DOI:10.1093/eurheartj/ehs274.; The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330-93. DOI:10.1093/ eurheartj/ehy136.; Molteni M, Crippa M, Orenti A, et al. Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation: The IDEA Study. Clin Drug Investig. 2019;39(4):355- 362. DOI:10.1007/s40261-018-0742-1.; Keller C, Katz R, Sarnak MJ, et al. Inflammatory biomarkers and decline in kidney function in the el- derty: the Cardiovascular Health Study. Nephrol Dial Transplant. 2010;25:119-24. DOI:10.1093/ndt/gfp429.; KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. DOI:10.1016/j.kint.2020.06.019.; Yao X., Tangri N, Gersh BJ, et al. Renal Outcomes in anticoagulated patients with atrial fibrillation. JACC. 2017:70:2621-32. DOI:10.1016/j.jacc.2017.09.1087.; https://www.rpcardio.com/jour/article/view/2426

الاتاحة: https://www.rpcardio.com/jour/article/view/2426
https://doi.org/10.20996/1819-6446-2021-04-04

المؤلفون: D. Andreev A., A. Zavyalov A., Д. Андреев А., А. Завьялов А.

المصدر: Cancer Urology; Том 17, № 3 (2021); 154-164 ; Онкоурология; Том 17, № 3 (2021); 154-164 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: prostate cancer, malignant tumor, quality control and quality assurance, cancer care, audit, UK, review, рак предстательной железы, злокачественное новообразование, контроль качества, организация онкологической помощи, аудит, Великобритания, обзор

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1453/1311; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1453/991; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1453/992; World Cancer Research Fund International. Prostate cancer statistics. American Institute for Cancer Research. [Internet]. 2021 (cited 2021 May 28). Available at: https://www.wcrf.org/dietandcancer/prostate-cancer-statistics/.; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. ПА. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.; National Prostate Cancer Audit. Quality Improvement. [Internet]. 2021 (cited 2021 Jun 18). Available at: https://www.npca.org.uk/quality-improvement/.; Aggarwal A., Nossiter J., Cathcart P. et al. Organisation of prostate cancer services in the English National Health Service. Clin Oncol (R Coll Radiol). 2016;28(8):482—9. DOI:10.1016/j.clon.2016.02.004.; Van Rijssen L.B., Koerkamp B.G., Zwart M.J. et al. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. HPB (Oxford) 2017;19(10):919—26. DOI:10.1016/j.hpb.2017.06.010.; Aggarwal A., Cathcart P., Payne H. et al. The National Prostate Cancer Audit — introducing a new generation of cancer audit. Clin Oncol (R Coll Radiol) 2014;26(2):90—3. DOI:10.1016/j.clon.2013.10.006.; Aggarwal A., Nossiter J., Parry M. et al. Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. Lancet Oncol 2021;22(5):e207—15. DOI:10.1016/S1470-2045(20)30558-1.; National Prostate Cancer Audit. Annual Report 2020 Executive Summary. [Internet]. 2021 (cited 2021 Jun 16). Available at: https://www.npca.org.uk/reports/npca-executive-summary-2020/.; Healthcare Quality Improvement Partnership (HQIP). National Prostate Cancer Audit. Annual Report 2020. Methodology Supplement. [Internet]. 2021 (cited 2021 Jun 11). Available at: https://www.npca.org.uk/reports/npca-methodology-supplement/.; NPCA Annual Report 2020 Infographics. [Internet]. 2021 (cited 2021 Jun 15). Available at: https://www.npca.org.uk/reports/npca-annual-report-2020-infographics/.; National Prostate Cancer Audit (NPCA). Annual Report 2020. Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April 2018 to 31 March 2019 (published January 2021). [Internet]. 2021 (cited 2021 Jun 15). Available at: https://www.npca.org.uk/reports/npca-annual-report-2020/.; Nossiter J., Sujenthiran A., Charman S.C. et al. Robot-assisted radical prostatectomy vi laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England. Br J Cancer 2018;118(4):489—94. DOI:10.1038/bjc.2017.454.; Szymanski K.M., Wei J.T., Dunn R.L., Sanda M.G. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010;76(5):1245—50. DOI:10.1016/j.urology.2010.01.027.; National Prostate Cancer Audit (NPCA). NPCA Outlier Policy 2020. [Internet]. 2021 (cited 2021 Jun 15). Available at: https://www.npca.org.uk/resources/npca-outlier-policy-2020/.; https://oncourology.abvpress.ru/oncur/article/view/1453

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1453
https://doi.org/10.17650/1726-9776-2021-17-3-154-164

المؤلفون: D. Andreev A., A. Kashurnikov Yu., A. Zavyalov A., Д. Андреев А., А. Кашурников Ю., А. Завьялов А.

المصدر: Malignant tumours; Том 11, № 1 (2021); 9-19 ; Злокачественные опухоли; Том 11, № 1 (2021); 9-19 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: audit, quality indicators, breast cancer, surgery, аудит, хирургическая техника, рак молочной железы

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/810/584; Verhoeven D, Allemani C, Kaufman C, Mansel R, Siesling S, Anderson B. Breast Cancer: global quality care optimizing care delivery with existing financial and personnel resources. ESMO open. 2020;4 (Suppl 2):e000 861.; Malycha P, Tyson S. National breast surgery audit. Aust N Z J Surg [Internet]. 2000 Dec 5;70 (12):834–6. Available from: http://doi.wiley.com/10.1046/j.1440–1622.2000.02002.x; Marinkovic M, Djordjevic N, Djordjevic L, Ignjatovic N, Djordjevic M, Karanikolic V. Assessment of the quality of life in breast cancer depending on the surgical treatment [published online ahead of print]. Support Care Cancer [Internet]. 2020 Oct 24; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33099655; Nasser JS, Chung WHJ, Gudal RA, Kotsis S V, Momoh AO, Chung KC. Quality Measures in Postmastectomy Breast Reconstruction: Identifying Metrics to Improve Care. Plast Reconstr surgery Glob open. 2020 Feb;8 (2):e2630.; van Bommel ACM, Spronk PER, Vrancken Peeters M-JTFD, Jager A, Lobbes M, Maduro JH, Mureau MAM, Schreuder K, Smorenburg CH, Verloop J, Westenend PJ, Wouters MWJM, Siesling S, Tjan-Heijnen VCG, van Dalen T. Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit. J Surg Oncol. 2017 Mar;115 (3):243–9.; Spronk PER, Volders JH, van den Tol P, Smorenburg CH, Vrancken Peeters M-JTFD. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2019 Feb;45 (2):110–7.; Cuncins-Hearn A V, Boult M, Babidge W, Zorbas H, Villanueva E, Evans A, Oliver D, Kollias J, Reeve T, Maddern G. National breast cancer audit: overview of invasive breast cancer management. ANZ J Surg. 2006 Aug;76 (8):745–50.; Jeevan R, Cromwell DA, Browne JP, Caddy CM, Pereira J, Sheppard C, Greenaway K, van der Meulen JHP. Findings of a national comparative audit of mastectomy and breast reconstruction surgery in England. J Plast Reconstr Aesthet Surg [Internet]. 2014 Oct;67 (10):1333–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24908545; Wang C, Li X, Su S, Wang X, Li J, Bao X, Liu M. Factors analysis on the use of key quality indicators for narrowing the gap of quality of care of breast cancer. BMC Cancer. 2019 Nov;19 (1):1099.; Eijkelboom A, Luyendijk M, Maaren M van, Munck L de, Schreuder K, Siesling S, Verloop J. © IKNL, oktober 2020. Borstkanker in Nederland trends 1989–2019 gebaseerd op cijfers uit de Nederlandse Kankerregistratie [Internet]. 2020. Available from: https://borstkanker.nl/sites/default/files/2020–10/RapportBorstkankerinNederland.pdf; Золотой стандарт диагностики и лечения рака молочной железы. Российское общество онкомаммологов. Версия 1.0 [Internet]. 2020 [cited 2021 Feb 10]. Available from: http://www.abvpress.ru/project/www.abvpress.ru/KR_ROOM_2020.pdf; Stordeur S, Vrijens F, Beirens K, Vlayen J, Devriese S, Van Eycken E. Kwaliteitsindicatoren in oncologie: borstkanker. Good Clinical Practice (GCP). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE). 2010. KCE Reports 150A. D2010 / 10.273 / 99 [Internet]. [cited 2021 Feb 10]. Available from: https://kce.fgov.be/sites/default/files/atoms/files/kce_150a_borstkanker.pdf; Weber WP, Morrow M, Boniface J de, Pusic A, Montagna G, Kappos EA, Ritter M, Haug M, Kurzeder C, Saccilotto R, Schulz A, Benson J, Fitzal F, Matrai Z, Shaw J, Peeters M-JV, Potter S, Heil J. Knowledge gaps in oncoplastic breast surgery. Lancet Oncol. 2020 Aug;21 (8):e375–85.; Kaufman CS. Increasing Role of Oncoplastic Surgery for Breast Cancer. Curr Oncol Rep. 2019;21 (12):111.; Urban C, Anselmi KF, Kuroda F, Schwartz JC. Oncoplasty as the standard of care in breast cancer surgery. Eur Oncol Haematol. 2014;10 (1):43–7.; Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. Lancet (London, England). 2021 Jan;397 (10 272):387–97.; NHS., MRC. GlobalSurg 3. Качество и результаты глобальной онкохирургии: проспективное, международное когортное исследование [Internet]. 2018 [cited 2021 Feb 11]. Available from: https://canceratlas.cancer.org/the-burden/breastcancer/; Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240 (2):205–13.; World Health Organization. International Agency for Research on Cancer. The Global Cancer Observatory [Internet]. 2021 [cited 2021 Feb 11]. Available from: https://gco.iarc.fr/; Kang SY, Kim YS, Kim Z, Kim HY, Kim HJ, Park S, Bae SY, Yoon KH, Lee SB, Lee SK, Jung K-W, Han J, Youn HJ. Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry. J Breast Cancer. 2020 Apr;23 (2):115–28.; National Breast Cancer Audit Reports%7C National Screening Unit [Internet]. [cited 2021 Feb 8]. Available from: https://www.nsu.govt.nz/health-professionals/breastscreen-aotearoa/publications-and-reports/national-breast-cancer-audit; The Royal Australasian College of Surgeons (RACS). BreastSurgANZ Quality Audit. Annual Report 2018. [Internet]. 2020 [cited 2021 Feb 25]. Available from: https://www.surgeons.org/; Salindera S, Ogilvy M, Spillane A. What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand? Breast. 2020 Jun;51:94–101.; Wouter Beke, Vlaams minister van Welzijn, Volksgezondheid en Gezin. Jaarrapport 2020 Bevolkingsonderzoek [Internet]. [cited 2021 Feb 9]. Available from: https://borstkanker.bevolkingsonderzoek.be/sites/default/files/atoms/files/Jaarrapport2020.pdf; Vlayen J, Stordeur S, Vrijens F, Van EyckenE. Kwaliteitsindicatoren in oncologie: voorwaarden voor het opzetten van een kwaliteitssysteem. Good Clinical Practice (GCP). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE). 2011. KCE Reports 152A. [Internet]. [cited 2021 Mar 1]. Available from: https://kce.fgov.be/en/quality-indicators-inoncology-prerequisites-for-the-set—up-of-a-quality-system; van Dam PA, Tomatis M, Marotti L, Heil J, Mansel RE, Rosselli Del Turco M, van Dam PJ, Casella D, Bassani LG, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, Kimmig R, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A. Time trends (2006 - 2015) of quality indicators in EUSOMA-certified breast centres. Eur J Cancer. 2017 Nov;85:15–22.; Borstsparende chirurgie — indicator B6 %7C UZ Leuven [Internet]. [cited 2021 Feb 9]. Available from: https://www.uzleuven.be/nl/borstkanker/kwaliteitsindicatoren-borstkanker/borstsparende-chirurgie-indicator-b6; Consensus Guideline on Breast Surgeon Quality Measurement [Internet]. 2018 [cited 2021 Feb 11]. Available from: https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Breast-Surgeon-Quality-Measurement.pdf; Landercasper J, Bailey L, Buras R, Clifford E, Degnim AC, Thanasoulis L, Fayanju OM, Tjoe JA, Rao R. The American Society of Breast Surgeons and Quality Payment Programs: Ranking, Defining, and Benchmarking More Than 1 Million Patient Quality Measure Encounters. Ann Surg Oncol. 2017 Oct;24 (10):3093–106.; The American Society of Breast Surgeons. Mastery of Breast SurgerySM [Internet]. [cited 2021 Feb 11]. Available from: https://masterybreastsurgeons.org/; Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Uitvoeringskader bevolkingsonderzoek borstkanker [Internet]. 2020 [cited 2021 Feb 9]. Available from: https://www.rivm.nl/documenten/uitvoeringskader-bevolkingsonderzoekborstkanker; Copyright © 2019 Stichting DICA. Alle rechten voorbehouden. NABON breast cancer audit (NBCA) jaarverslag uitkomsten 2019. 16 oktober 2020 [Internet]. [cited 2021 Feb 9]. Available from: https://dica.nl/media/2511/NBCAJaarverslag2019.pdf; Copyright © 2019 Stichting DICA. Alle rechten voorbehouden. NBCA indicatoren 2019 [Internet]. 2019 [cited 2020 Oct 21]. Available from: https://dica.nl/media/2453/NBCAindicatoren2019.pdf; NHS Digital. Breast Screening Programme. [Internet]. [cited 2021 Feb 20]. Available from: https://digital.nhs.uk/dataand-information/publications/statistical/breast-screening-programme/england---2019–20; NHS Breast Screening Programme & Association of Breast Surgery. An audit of screen detected breast cancers for the year of screening April 2018 to March 2019 [Internet]. 2020 [cited 2021 Feb 11]. Available from: https://associationofbreastsurgery.org.uk/media/311352/nhs-bsp-abs-audit-2018–2019.pdf; The Health Foundation. Breast cancer care Quality indicators. [Internet]. 2019 [cited 2021 Feb 20]. Available from: https://www.health.org.uk/sites/default/files/2019–11/breast_cancer_care_quality_indicators_-_q04a_the_measurement_maze.pdf; NICE. Breast cancer. [Internet]. 2016 [cited 2021 Feb 20]. Available from: https://www.nice.org.uk/guidance/qs12/chapter/Introduction; NABCOP. Healthcare Quality Improvement Partnership. National Audit of Breast Cancer in Older Patients [Internet]. London; 2020 [cited 2021 Feb 8]. Available from: https://www.nabcop.org.uk/; NHS. National Mastectomy and Breast Reconstruction Audit, Annual Report [Internet]. [cited 2021 Feb 11]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/national-mastectomy-and-breastreconstruction-audit-annual-report; The Royal College of Surgeons of England. National Mastectomy and Breast Reconstruction Audit — Fourth Report [Internet]. 2011 [cited 2021 Feb 8]. Available from: https://www.rcseng.ac.uk/library-and-publications/rcspublications/docs/mastectomy-breast-4/; Jeevan R. Reconstructive utilisation and outcomes following mastectomy surgery in women with breast cancer treated in England. Ann R Coll Surg Engl. 2020 Feb;102 (2):110–4.; The Association of Breast Surgery. UK National Flap Registry [Internet]. 2021 [cited 2021 Feb 11]. Available from: https://associationofbreastsurgery.org.uk/; https://www.malignanttumors.org/jour/article/view/810

الاتاحة: https://www.malignanttumors.org/jour/article/view/810
https://doi.org/10.18027/2224-5057-2021-11-1-9-19

المؤلفون: K. Mirzaev B., D. Ivashchenko V., I. Volodin V., E. Grishina A., K. Akmalova A., A. Kachanova A., A. Skripka I., R. Minnigulov M., T. Morozova E., O. Baturina A., A. Levanov N., T. Shelekhova V., A. Kalinkin I., D. Napalkov A., A. Sokolova A., D. Andreev A., I. Sychev N., P. Bochkov O., D. Sychev A., К. Мирзаев Б., Д. Иващенко В., И. Володин В., Е. Гришина А., К. Акмалова А., А. Качанова А., А. Скрипка И., Р. Миннигулов М., Т. Морозова Е., О. Батурина А., А. Леванов Н., Т. Шелехова В., А. Калинкин И., Д. Напалков А., А. Соколова А., Д. Андреев А., И. Сычев Н., П. Бочков А., Д. Сычев А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 16, No 5 (2020); 670-677 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 5 (2020); 670-677 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: dabigatran, rivaroxaban, pharmacogenetics, direct oral anticoagulants, sequencing, personalized medicine, дабигатран, ривароксабан, фармакогенетика, прямые оральные антикоагулянты, секвенирование, персонализированная медицина

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2288/2044; https://www.rpcardio.com/jour/article/view/2288/2069; Alalwan A.A., Voils S.A., Hartzema A.G. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237-44. DOI:10.2146/ajhp160756.; Loo S.Y., Dell'Aniello S., Huiart L., et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096-106. DOI:10.1111/bcp.13299.; Ziakas P.D., Kourbeti I.S., Poulou L.S., et al. Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect". PLoS One. 2018;13(6):e0198674. DOI:10.1371/journal.pone.0198674.; Philippidis A. Top 15 Best-Selling Drugs of 2018: Sales for most treatments grow year-over-year despite concerns over rising prices. Genetic Engineering & Biotechnology News. 2019 39(4):16-7.; Alfirevic A., Downing J., Daras K., et al. Has the introduction of direct oral anticoagulants (DOACs) in England increased emergency admissions for bleeding conditions? A longitudinal ecological study. BMJ Open. 2020;10(5):e033357. DOI:10.1136/bmjopen-2019-033357.; Ragia G., Manolopoulos V.G. Pharmacogenomics of anticoagulation therapy: the last 10 years. Pharmacogenomics. 2019;20(16):1113-7. DOI:10.2217/pgs-2019-0149.; Kanuri S.H., Kreutz R.P. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. J Pers Med. 2019;9(1):7. DOI:10.3390/jpm9010007.; Whirl-Carrillo M., McDonagh E.M., Hebert J.M., et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414-7. DOI:10.1038/clpt.2012.96.; Государственный реестр лекарственных средств [цитировано 20.07.2020. Доступно на: https://grls.rosminzdrav.ru/Default.aspx.; Gong I.Y., Kim R.B. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7 Suppl):S24-S33. DOI:10.1016/j.cjca.2013.04.002.; Genome Aggregation Database [cited by Jul 20, 2020]. Available from: https://gnomad.broadinstitute.org.; Moner-Banet T., Alberio L., Bart P.A. Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature. Hamostaseologie. 2020;40(2):184-200. DOI:10.1055/a-1113-0655.; Shi J., Wang X., Nguyen J.H., et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016;119:76-84. DOI:10.1016/j.bcp.2016.09.003.; Paré G., Eriksson N., Lehr T., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404-12. DOI:10.1161/CIRCULATIONAHA.112.001233.; Dimatteo C., D'Andrea G., Vecchione G., et al. Pharmacogenetics of dabigatran etexilateinterindividual variability. Thromb Res. 2016;144:1-5. DOI:10.1016/j.thromres.2016.05.025.; Sychev D.A., Levanov A.N., Shelekhova T.V., et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [published correction appears in Pharmacogenomics Pers Med. 2018 Sep 26;11:167]. Pharmacogenomics Pers Med. 2018;11:127-37. DOI:10.2147/PGPM.S169277.; Gouin-Thibault I., Delavenne X., Blanchard A., et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273-83. DOI:10.1111/jth.13577.; Sánchez Pascua T. Carboxylesterase 1 genetic variability, expression and potential for drug-drug interations. Diss. University of Liverpool, 2014 [cited by Jul 20, 2020]. Available from: https://livrepository.liverpool.ac.uk/2006752/1/SanchezTer_Sep2014_2006752.pdf.; Lorenzini K.I, Daali Y., Fontana P., et al. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol. 2016;7:494. DOI:10.3389/fphar.2016.00494.; Sennesael A.L., Larock A.S., Douxfils J., et al. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J. 2018;16:28. DOI:10.1186/s12959-018-0183-3.; https://www.rpcardio.com/jour/article/view/2288

الاتاحة: https://www.rpcardio.com/jour/article/view/2288
https://doi.org/10.20996/1819-6446-2020-10-05

المؤلفون: A. Shilova S., E. Gilyarova M., D. Andreev A., D. Shchekochikhin Yu., N. Novikova A., M. Gilyarov Yu., А. Шилова С., Е. Гилярова М., Д. Андреев А., Д. Щекочихин Ю., Н. Новикова А., М. Гиляров Ю.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 14, No 3 (2018); 361-369 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 3 (2018); 361-369 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-3

مصطلحات موضوعية: myocardial infarction, myocardial infarction with non-obstructive coronary arteries, atrial fibrillation, coronary embolism, инфаркт миокарда, инфаркта миокарда без обструкции коронарных артерий, фибрилляция предсердий, эмболия коронарных артерий

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1691/1655; Pasupathy S., Tavella R., Beltrame J.F. The What, When, Who, Why, How and Where of Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA). Circ J. 2016;80(1):11-6. doi:10.1253/circj.CJ-15-1096.; Pasupathy S., Tavella R., Beltrame J.F. Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA): The Past, Present, and Future Management. Circulation. 2017;135(16):1490-3. doi:10.1161/CIRCULATIONAHA.117.027666.; Shibata T., Kawakami S., Noguchi T., et al. Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Due to Coronary Artery Embolism. Circulation. 2015;132(4):241-50. doi:10.1161/CIRCULATIONAHA.114.015134.; El Sabbagh A., Al-Hijji M.A., Thaden J.J., et al. Cardiac myxoma: the great mimicker. J Am Coll Cardiol Img. 2017;10:203–6. doi:10.1016/j.jcmg.2016.06.018.; Panos A., Kalangos A., Sztajzel J. Left atrial myxoma presenting with myocardial infarction. Case report and review of the literature. Int J Cardiol. 1997;62:73-5. doi:10.1016/S0167-5273(97) 00178-2.; Braun S., Schrötter H., Reynen K., et al. Myocardial infarction as complication of left atrial myxoma. Int J Cardiol. 2005;101:115-21. doi:10.1016/j.ijcard.2004.08.047.; Waksman R., Ghazzal Z.M., Baim D.S., et al. Myocardial infarction as a complication of new interventional devices. Am J Cardiol. 1996;78:751-6. doi:10.1016/S0002-9149(96)00415-8.; Khawaja M.Z., Sohal M., Valli H., et al. Standalone balloon aortic valvuloplasty: Indications and outcomes from the UK in the transcatheter valve era. Catheter Cardiovasc Interv. 2013;81:366-73. doi:10.1002/ccd.24534.; Chikkabasavaiah N., Rajendran R. Percutaneous coronary intervention for coronary thromboembolism during balloon mitral valvuloplasty in a pregnant woman. Heart Lung Circ. 2016;25:e29-31. doi:10.1016/j.hlc.2015.06.824.; Niccoli G., Scalone G., Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management. Eur Heart J. 2015;36(8):475-81. doi:10.1093/ eurheartj/ehu469.; Raphael C.E., Heit J.A., Reeder G.S., et al. Coronary Embolus An Underappreciated Cause of Acute Coronary Syndromes. JACC Cardiovasc Interv. 2018;11(2):172-80. doi:10.1016/j.jcin.2017. 08.057.; Jolly S.S., Cairns J.A., Yusuf S., et al. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet. 2016;387:127-35. doi:10.1016/S0140-6736(15)00448-1.; Fröbert O., Lagerqvist B., Olivecrona G.K., et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587-97. doi:10.1056/NEJMoa1308789.; Jolly S.S., James S., Džavík V., et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis. Circulation. 2017;135(2):143-52. doi:10.1161/CIRCULATIONAHA.116.025371.; Migliorini A., Stabile A., Rodriguez A.E., et al. Comparison of angiojet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;56:1298-306. doi:10.1016/j.jacc.2010.06.011.; Mentzelopoulos S.D., Kokotsakis J.N., Romana C.N., Karamichali E.A. Intracoronary thrombolysis and intraaortic balloon counterpulsation for the emergency treatment of probable coronary embolism after repair of an acute ascending aortic dissection. Anesth Analg. 2001;93:56-9. doi:10.1097/00000539-200107000-00013.; Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi:10.1056/NEJMoa1009638.; Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561.; Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907.; Camaro C., Aengevaeren W.R.M. Acute myocardial infarction due to coronary artery embolism in a patient with atrial fibrillation. Neth Heart J. 2009;17:297-9. doi:10.1056/NEJMoa1310907.; Acikel S., Dogan M., Aksoy M.M., Akdemir R. Coronary embolism causing non-ST elevation myocardial infarction in a patient with paroxysmal atrial fibrillation: treatment with thrombus aspiration catheter. Int J Cardiol. 2011;149:e33-35. doi:10.1016/j.ijcard.2009.03.077.; Kleczyński P., Dziewierz A., Rakowski T., et al. Cardioembolic acute myocardial infarction and stroke in a patient with persistent atrial fibrillation. Int J Cardiol. 2012;161(3):e46-7. doi:10.1016/j.ijcard.2012.04.018.; Gagliardi L., Guerbaai R.A., Marliere S., et al. Coronary embolization following electrical cardioversion in a patient treated with dabigatran. Int J Cardiol. 2014;175:571-2. doi:10.1016/j.ijcard.2014.05.030.; Mallouppas M., Christopoulos C., Watson W., et al. An uncommon complication of atrial fibrillation. Oxford Medical Case Reports. 2015;3:232-4. doi:10.1093/omcr/omv017.; Agewall S., Beltrame J.F., Reynolds H.R., et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143-53. doi:10.1093/eurheartj/ehw149.; https://www.rpcardio.com/jour/article/view/1691

الاتاحة: https://www.rpcardio.com/jour/article/view/1691
https://doi.org/10.20996/1819-6446-2018-14-3-361-369

المؤلفون: D. Andreev A., Д. Андреев А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 10, No 6 (2014); 679-687 ; Рациональная Фармакотерапия в Кардиологии; Vol 10, No 6 (2014); 679-687 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2014-10-6

مصطلحات موضوعية: functional platelet activity, antiplatelet therapy, high residual platelet reactivity, aggregometry, функциональная активность тромбоцитов, антитромбоцитарная терапия, высокая остаточная реактивность тромбоцитов, агрегатометрия

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/309/324; Belenkov YN, Oganov RG. Cardiology: national guidance. Moscow: GEOTAR-Media; 2010. Russian (Беленков Ю.Н., Оганов Р.Г. Кардиология: национальное руководство. М.: ГЭОТАР-Медиа; 2010).; Boytsov SA, Chuchalin AG, Arutyunov GP, et al. Prevention of chronic noninvasive-infectious diseases. Recommendations. Moscow; 2013. Available at: http://www.gnicpm.ru/UserFiles/Profilaktika_khronicheskikh_neinfekcionnykh_zabolevanijj.pdf. Accessed by 06/12/2014. Russian (Бойцов С.А., Чучалин А.Г., Арутюнов Г.П. и др. Профилактика хронических неинфекционных заболеваний. Рекомендации. М.; 2013. Доступно на: http://www.gnicpm.ru/UserFiles/Profilaktika_khronicheskikh_neinfekcionnykh_zabolevanijj.pdf. Проверено 06.12.2014).; National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (6) suppl 2: 1-64. Russian (Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная Терапия и Профилактика 2011; 10 (6) приложение 2: 1-64).; Martsevich SY, Kutishenko NP, Ginzburg ML, et al. Efficacy, safety, and adherence to antiplatelet therapy in patients at high risk of thrombotic complications. Available at:http://cardiodrug.ru/media/file/binary/2013/8/5/201123960374/effektivnost-bezopasnost-i-priverzhennost-anti.pdf?srv=app1. Accessed by 06/12/2014. Russian (Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л. и др. Эффективность, безопасность и приверженность антитромбоцитарной терапии у пациентов с высоким риском тромботических осложнений. Доступно на: http://cardiodrug.ru/media/file/binary/2013/8/5/201123960374/effektivnost-bezopasnost-i-priverzhennost-anti.pdf?srv=app1. Проверено 06.12.2014).; Fuster V. Guided Antithrombotic Therapy: Current Status and Future Research Direction. Report on a National Heart, Lung and Blood Institute Working Group. Circulation 2012;126:1645-62.; Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947; Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke 2014;45: 2160-236.; Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34: 2949-3003.; Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-701.; Wenger N.K. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): Highlights for the Clinician. Clin Cardiol 2012; 35(1): 3-8.; Windecker S, Kolh P, Alfonso F, et al 2014 ESC/EACTS Guidelines on myocardial Revascularization. Eur Heart J 2014;35(37):2541-619.; Giorgi MA, Di Girolamo G, González CD. Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin. Pharmacother 2010; 11(14):2391-403.; The Global Registry of Acute Coronary Events. Available at: http://www.outcomes-umassmed.org/grace/. Accessed by 06.12.2014; Trenk D, Stone GW, Gawaz M, et al. A Randomised Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 2012; 59: 2159-64.; Garabedian T., Alam S. High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther 2013;3(1):23-37.; Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/IS TH. J Thromb Haemost 2013; 11: 1183-9.; Stone GW, Witzenbichler B, Weisz G, et al, Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382(9892):614-23.; Witzenbichler B. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPTDES) study. Circulation 2014;129(4):463-70.; Janssen P.W.A., ten Berg J. M., Hackeng C. M. The use of platelet function testing in PCI and CABG patients. Blood Rev 2014; 28(3): 109-21.; Bonello L, Mancini J, Pansieri M, et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012;10:1999-2005.; Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474-83.; Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010;56: 317-8.; Larsen SB, Grove EL, Hvas AM, Kristensen SD. Platelet Turnover in Stable Coronary Artery Disease Influence of Thrombopoietin and Low-Grade Inflammation. PLoS One 2014;9(1):e85566.; Lordkipanidze M. Platelet Turnover in Atherothrombotic Disease. Current Pharmaceutical Design 2012;18 (33):5328-43.; Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 Genetic Polymorphisms and the Responseto Prasugrel Relationship Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes. Circulation 2009;119:2553-60.; Morel O, Muller C, Jesel L, et al. Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrol Dial Transplant 2013;28(8):1994-2002.; Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154 (2):221-31.; Mirzayev KB, Sychev DA, DA Andreev, Prokofiev AB. The value of pharmacogenetic testing for SYP2S19 to personalize the use of antiplatelet agents in cardiology practice. Ration Pharmacother Cardiol 2013; (4): 404-8. Russian (Мирзаев К.Б., Сычев Д.А., Андреев Д.А., Прокофьев А.Б. Значение фармакогенетического тестирования по СYP2С19 для персонализации применения антиагрегантов в кардиологической практике. Рациональная Фармакотерапия в Кардиологии 2013;(4): 404-8).; Campo G, Fileti L, de Cesare N, et al. Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention A 3T/2R (Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel) Trial Substudy. J Am Coll Cardiol 7 2010;56:1447-55.; Mahla E. Platelet Function Measurement–Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery. The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study. Circ Cardiovasc Interv 2012;5:261-9.; Mirzaev K., Sychev D. Cytochrome 2C19 Enzyme Polymorphism Frequency in Different Indigenous Ethnic Groups in Russian Federation: A Systematic Review. J Pharmacogenomics Pharmacoproteomics 2014; 5:3; Laine M, Toesca R, Berbis J, et al. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thromb Res 2013;132(1):e15-8.; Aradi D, Komócsi A, Price MJ, et. al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2013;167(5):2140-8.; Siller-Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2013;167(5):2018-23.; Siller-Matula JM1, Gruber C2, Francesconi M, et al.The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Sci (Lond) 2015;128(2):121-30.; Aradi D, Tornyos A, Pintér T, et al. Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing Impact of Prasugrel and High-Dose Clopidogrel. JACC 2014; 63(11): 1061-70.; Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209-15.; Ferraris VA, Saha SP, Oestreich JH, et al. 2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. Ann Thorac Surg 2012; 94:1761-81.; Kristensen S.D. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J 2014;35(35):2383-431.; Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 2004;34(2):341-8.; https://www.rpcardio.com/jour/article/view/309

الاتاحة: https://www.rpcardio.com/jour/article/view/309
https://doi.org/10.20996/1819-6446-2014-10-6-679-687

المؤلفون: K. Mirzaev B., D. Sychev A., D. Andreev A., A. Prokofiev B., К. Мирзаев Б., Д. Сычев А., Д. Андреев А., А. Прокофьев Б.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 9, No 4 (2013); 404-408 ; Рациональная Фармакотерапия в Кардиологии; Vol 9, No 4 (2013); 404-408 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2013-9-4

مصطلحات موضوعية: resistance to clopidogrel, pharmacogenetics, CYP2C19, резистентность к клопидогрелу, фармакогенетика, CYP2С19

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/99/106; Klingenberg M. Pigments of liver microsomes. Arch Biochem Biophys 1958;75:376-86.; Garfinkel D. Studies on pig liver microsomes. Enzymes and pigment composition of different micro- somal fractions. Arch Biochem Biophys 1958;77:493-509.; Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003;348(6):538-49.; Goldstein, J. A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52: 349-55.; Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20): 2569-619.; Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32(23): 2999-3054.; Yusuf S, Zhao F., Mehta SR, et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Tri- al Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.; Chen ZM, Jiang LX, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial in- farction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.; Isaacs D, Lander C, McNeil J, et al. Clopidogrel – haemorrhage and haematological disorders. Aust Adv Drug Reactions Bull 2004; 23(4): 14-5.; Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352(12):1179-89.; Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360(4):354-62.; Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Ar- terioscler Thromb Vasc Biol 2006; 26(8):1895-900.; Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80(5):486-501.; Simon T, Verstuyft C, Mary-Krause M, et al Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360(4):363-375.; Weiss EJ, Bray PF, Tayback M, et al. A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis. N Engl J Med 1996; 334:1090-1094.; Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G >A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percu- taneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51:1925-34.; Shuldiner AR, O'Connell JR, GurbelPA et al. Influence of CYP2C19 polymorphism on antiplatelet effects of clopidogrel and long-term recurrent ischemic event occurrence. JAMA 2009; 302:849-58.; Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30 (8): 916-22.; Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304(16):1821-30.; Holmes MV, Perel P, Shah T et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306(24):2704-14.; Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20): 2569-19.; FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at: http://www.fda.gov/Drugs/DrugSafety/ Postmarket- DrugSafetyInformationforPatientsandProviders/ucm203888.htm. Date of access 12.08.2013.; Levine GN, Bates ER, Blankenship JC, et al. ACCF /AHA/SCAI Guideline for Percutaneous Coronary Intervention. JACC 2011; 58(24):44-122.; Komarov LA, Panchenko EP, AE Donnikov and other factors that determine the clinical efficacy of clopi- dogrel and prognosis of patients with stable coronary heart disease. Cardiology 2011, (2): 8-18. Russian (Комаров Л.А., Панченко Е.П., Донников А.Е. и др. Факторы, определяющие клиническую эффективность клопидогрела и прогноз больных со стабильной формой ишемической болезни сердца. Кардиология 2011; (2): 8-18).; Galyavich AS, Valeyeva DD, Minnetdinov R.Sh. and other CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel. Cardiology 2012, (4): 20-4. Russian (Галявич А.С, Валеева Д.Д., Миннетдинов Р.Ш. и др. Полиморфизм гена CYP2C19 у больных инфарктом миокарда, применяющих клопидогрел. Кардиология 2012; (4): 20-4).; Kudzoeva ZF, Boqueria, LA, La Boqueria, OL Pharmacogenetic testing ispolzovnaiem modern techniques in patients taking clopidogrel, as a basis of personalized medicine. Proceedings of the annual session of the XVII Scientific Center of Cardiovascular Surgery. AN Bakuleva. Moscow 2013: 111. Russian (Кудзоева З.Ф., Бокерия Л.А., Бокерия О.Л. Фармакогенетическое тестирование с использованием современных методик у пациентов, принимающих клопидогрель, как основа персонализированной медицины. Материалы XVII ежегодной сессии научного центра сердечнососудистой хирургии им. А.Н. Бакулева. Москва 2013: 111).; Bonello L, Camoin-Jau L, Arques L et al. Adjusted clopidogrel loading doses according to vasodila- tor-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol2008;51:1404-1411; Mega J, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60.; Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121:1188-99.; Jeong YH, Lee SW, Choi BR et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101-09.; Von Beckerath N, Taubert D, Pogatsa-Murray G et al. Absorption, metabolization, and antiplatelet ef- fects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intra- coronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005;112:2946-50.; Gladding P, Webster M, Zeng I et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1:612-9.; Aleil B, L. Jacquemin L, De Poli F et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008;1:631-8.; Price MJ. Berger PB, Teirstein PS, et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305(11):1097-105.; Reese ES, Mullins CD, Beitelshees AL, et al. Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel. Pharmacotherapy 2012;32(4):323-32.; Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Cir- culation 2010;121(4):512-8.; https://www.rpcardio.com/jour/article/view/99

الاتاحة: https://www.rpcardio.com/jour/article/view/99
https://doi.org/10.20996/1819-6446-2013-9-4-404-408

المؤلفون: K. Mirzaev B., R. Kazakov E., V. Smirnov V., D. Andreev A., D. Sychev A., К. Мирзаев Б., Р. Казаков Е., В. Смирнов В., Д. Андреев А., Д. Сычев А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 11, No 4 (2015); 344-354 ; Рациональная Фармакотерапия в Кардиологии; Vol 11, No 4 (2015); 344-354 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2015-11-4

مصطلحات موضوعية: CYP2C19*2, acute coronary syndrome, CYP3A4, pharmacogenetics, clopidogrel, P2Y12-receptor blockers, острый коронарный синдром, фармакогенетика, клопидогрел, блокаторы P2Y12-рецепторов

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/125/134; https://www.rpcardio.com/jour/article/view/125/135; Ruggeri Z.M., Platelets in atherothrombosis, Nature Med, 2002;8:1227-34.; Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38):2949-3003.; Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33(20):2569-619.; Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054.; Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303(8):754-762.; Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on ’high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009;102:719-27.; Voisin S1, Bongard V, Tidjane MA, et al. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. Thromb Haemost2011;106(2):227-9.; Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.; Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.; Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992;44(3):527-32.; Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9; Beitelshees AL, Horenstein RB, Vesely MR, Mehra MR, Shuldiner AR. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther. 2011;89:455-9.; Lamba JK, Lin YS, Thummel K, Daly A, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121-32.; Mičuda S, Šišpera L, HodačM, et al. Diurnal Variation of 6β-Hydroxycortisol in Cardiac Patients. Physiol Res 2007; 56: 307-313.; Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50: 1541-1547.; Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.; Pettersen AÅ, Seljeflot I, Abdelnoor M, et al. High on aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc. 2012;1:e000703; Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382: 614-23.; Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost. 2010;103(4):841-848.; Aradi D, Kom´ ocsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160(3):543-551.; Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35(4):209-215.; Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304(16):1821-30.; Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-23.; Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122.; Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645-81.; Tatarunas V, Jankauskiene L, Kupstyte N, et al. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. Blood Coagul Fibrinolysis 2014;25(4):369-74.; Sulimov V.A., Moroz E.V. Resistance to antiplatelet drugs (aspirin, clopidogrel) in patients undergoing elective percutaneous coronary intervention. Rational Pharmacother. Card. 2012;8(1):23-30. Russian (Сулимов В.А., Мороз Е.В. Резистентность к антитромбоцитарным препаратам (аспирину, клопидогрелу) у пациентов, подвергающихся элективному стентированию коронарных артерий. Рациональная фармакотерапия в кардиологии 2012;8(1):23-30.); Komarov A.L., Shahmatova O.O., Iljushhenko T.A., et al. Assessing Risk of Cardiovascular Events in Clopidogrel-Treated Patients with Stable CHD: Platelet Function or Genetic Testing? Doktor.Ru 2012; 6:11-; Russian (Комаров А.Л., Шахматова О.О., Илющенко Т.А., и др. Оценка риска сердечно-сосудистых осложнений у больных стабильной ИБС, получающих клопидогрел: функция тромбоцитов или генетические исследования? Доктор.Ру 2012; 6:11-19); Goluhova E.Z., Grigorjan M.V., Rjabinina M.N., et al. The platelet reactivity after percutaneous coronary intervention in patients with double antiplatelet therapy: impact of genetic polymorphisms. Kreativnaja kardiologija 2014; 3:39-52. Russian (Голухова Е.З., Григорян М.В., Рябинина М.Н., и др. Современные аспекты фармакогенетики клопидогрела и его клиническое значение. Креативная кардиология 2014; 3:39-52.); Mazurov A.V., Zjurjaev I.T., Haspekova S.G., et al. Factors influencing platelet aggregation in patients with acute coronary syndrome. Terapevticheskij arhiv 2014; 9:83-89. Russian (Мазуров А.В., Зюряев И.Т., Хаспекова С.Г., и др. Факторы, влияющие на агрегационную активность тромбоцитов у больных с острым коронарным синдромом. Терапевтический архив 2014; 9:83-89.); Hu ZY, Zhao YS, Wu D et al. Еndogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans. Clin Chim Acta 2009;408(1-2): 92-7.; https://www.rpcardio.com/jour/article/view/125

الاتاحة: https://www.rpcardio.com/jour/article/view/125
https://doi.org/10.20996/1819-6446-2015-11-4-344-354

المؤلفون: В. Васильев Н., А. Нестеренко И., Т. Робенкова В., Т. Подкопаева И., Д. Андреев А., Е. Афанасьев А., И. Сенникова А.

المصدر: Bulletin of Siberian Medicine; Том 4 (2005): Приложение 1; 160-161 ; Бюллетень сибирской медицины; Том 4 (2005): Приложение 1; 160-161 ; 1819-3684 ; 1682-0363 ; undefined

وصف الملف: application/pdf

Relation: https://bulletin.tomsk.ru/jour/article/view/4104/2847; https://bulletin.tomsk.ru/jour/article/view/4104; undefined

الاتاحة: https://bulletin.tomsk.ru/jour/article/view/4104